Oral vinorelbine (NVBO) in combination with trastuzumab (HER) in metastatic breast cancer (MBC): Data on efficacy and safety when administered in first- or second-line treatment.

Illarramendi, J.J.; Blancas, Isabel; Bueso, P.; Carabantes, F.; Marqués, Eduardo Polo; Gil, Eva Ciruelos; Corral, Mónica; Pérez, F.J.

doi:10.1200/jco.2010.28.15_suppl.e11508

Cited by 4 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…В данном исследовании использовали инъекционную форму винорелбина, однако согласно данным других исследований возможна его замена на пероральную форму без потери эффективности. Так, применение трастузумаба в сочетании с Навельбином позволяет достичь ОО у 60-80% больных, с медианой ВДП 9-12 месяцев и медианой ОВ от 2,5 до 3 лет [19][20][21][22]. А отсутствие потенциального негативного влияния на миокард, возможно, позволит в дальнейшем применять винорелбин в сочетании с новыми анти-HER2-препаратами.…”

unclassified

Modern Possibilities of Application of Preparation Navelbine® in the Treatment of Metastatic Breast Cancer

Болотина¹

2016

Issled. prakt. med. (Print)

View full text Add to dashboard Cite

Drug therapy of disseminated forms of breast cancer involves the use of mono-and polychemotherapy with the possible combination with target-therapy in various clinical situations. The article presents the choices of treatment approaches, demonstrated the efficacy and safety of chemotherapeutic regimens on the basis of vinorelbine. Резюме Лекарственная терапия диссеминированных форм рака молочной железы предполагает использование режимов моно-и полихимиотерапии с возможным сочетанием с препаратами таргетной терапии в различных клинических ситуациях. В статье представлены варианты выбора лечебных подходов, продемонстрирована эффективность и безопасность химиотерапевтических режимов на основе винорелбина. Ключевые слова: винорелбин, метастатический рак молочной железы (мРМЖ), метрономная химиотерапия

show abstract

unclassified

Modern Possibilities of Application of Preparation Navelbine® in the Treatment of Metastatic Breast Cancer

Болотина¹

2016

Issled. prakt. med. (Print)

View full text Add to dashboard Cite

show abstract

Oral vinorelbine in metastatic breast cancer: A review of current clinical trial results

Aapro

Fínek

2012

Cancer Treatment Reviews

View full text Add to dashboard Cite

Current regimens for use of vinorelbine in metastatic breast cancer: role and place of oral dosage form, metronome therapy, combinations with anti-HER 2 drugs

Артамонова

2020

Medicinskij alfavit

View full text Add to dashboard Cite

The purpose of the treatment of metastatic breast cancer is overall survival improvement, thus the search for new effective regimes of chemotherapy with low toxicity is especially important. Therefore chemotherapy is one of the options for the treatment of metastatic breast cancer, for instance oral vinorelbine has shown consistant efficacy with a low toxicity profile. In this framework, an active and well tolerated oral CT option provides additional benefits for patients such as the possibilty of intake of the treatment at home and allows avoiding an intravenous infusion and alopecia if that is a priority for the patients. According to experts’ opinions vinorelbine is an efficient choice for first line of chemotherapy of metastatic breast cancer along with anthracyclines and taxanes. A meta-analysis of published trials concluded that longer first-line CT duration is associated with a marginally longer OS and a substantially longer PFS. In this context oral vinorelbine may be chosen as a preferable treatment since treament with oral vinorelbine can go on substantianaly longer than treatment with many other drugs. Vinorelbine yielded equal or superiour results to both paclitaxel and docetaxel, when combined with trastuzumab in the HER-2-positive ABC in the HERNATA and TRAVIOTA trials. And finally oral vinorelbine can be used in new metronomic regimens in which drugs are adminstered frequently or continuously. This kind of treatment maintains low, prolonged and pharmacologically active plama concentrations of drugs to avoid toxicity associated with traditional chemotherapy regimens, while achieveing tumor responce. Thus vinorelbine can be used as one of the options of metastatic breast cancer treatment.

show abstract

Oral vinorelbine (NVBO) in combination with trastuzumab (HER) in metastatic breast cancer (MBC): Data on efficacy and safety when administered in first- or second-line treatment.

Cited by 4 publications

References 0 publications

Modern Possibilities of Application of Preparation Navelbine® in the Treatment of Metastatic Breast Cancer

Modern Possibilities of Application of Preparation Navelbine® in the Treatment of Metastatic Breast Cancer

Oral vinorelbine in metastatic breast cancer: A review of current clinical trial results

Current regimens for use of vinorelbine in metastatic breast cancer: role and place of oral dosage form, metronome therapy, combinations with anti-HER 2 drugs

Contact Info

Product

Resources

About